{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:57:59Z","timestamp":1793059079008,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T00:00:00Z","timestamp":1592352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2019R1A2C2002393"],"award-info":[{"award-number":["NRF-2019R1A2C2002393"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00262-020-02635-3","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T08:02:47Z","timestamp":1592380967000},"page":"2441-2452","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Factors associated with ocular adverse event after immune checkpoint inhibitor treatment"],"prefix":"10.1007","volume":"69","author":[{"given":"Yong Joon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihei Sara","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junwon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Chul","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-im","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk Ho","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5054-9470","authenticated-orcid":false,"given":"Christopher Seungkyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,17]]},"reference":[{"key":"2635_CR1","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"2635_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521\u20132532. https:\/\/doi.org\/10.1056\/NEJMoa1503093","journal-title":"N Engl J Med"},{"key":"2635_CR3","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","volume":"38","author":"LA Dalvin","year":"2018","unstructured":"Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA (2018) Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina 38:1063\u20131078. https:\/\/doi.org\/10.1097\/IAE.0000000000002181","journal-title":"Retina"},{"key":"2635_CR4","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0367","journal-title":"Cancer Discov"},{"key":"2635_CR5","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, Lennon VA, Celis E, Chen L (2002) Tumor-associated B7\u2013H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800. https:\/\/doi.org\/10.1038\/nm730","journal-title":"Nat Med"},{"key":"2635_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s10067-019-04451-2","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252\u2013264. https:\/\/doi.org\/10.1007\/s10067-019-04451-2","journal-title":"Nat Rev Cancer"},{"key":"2635_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"2635_CR8","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","volume":"27","author":"MR Robinson","year":"2004","unstructured":"Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA (2004) Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 27:478\u2013479. https:\/\/doi.org\/10.1097\/00002371-200411000-00008","journal-title":"J Immunother"},{"key":"2635_CR9","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","volume":"6","author":"L Hahn","year":"2016","unstructured":"Hahn L, Pepple KL (2016) Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect 6:14. https:\/\/doi.org\/10.1186\/s12348-016-0082-3","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"2635_CR10","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40425-016-0170-9","volume":"4","author":"MA Wilson","year":"2016","unstructured":"Wilson MA, Guld K, Galetta S, Walsh RD, Kharlip J, Tamhankar M, McGettigan S, Schuchter LM, Fecher LA (2016) Acute visual loss after ipilimumab treatment for metastatic melanoma. J Immunother Cancer 4:66. https:\/\/doi.org\/10.1186\/s40425-016-0170-9","journal-title":"J Immunother Cancer"},{"key":"2635_CR11","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.5301\/ejo.5000724","volume":"26","author":"K Abu Samra","year":"2016","unstructured":"Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD (2016) A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 26:e46\u2013e48. https:\/\/doi.org\/10.5301\/ejo.5000724","journal-title":"Eur J Ophthalmol"},{"key":"2635_CR12","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1002\/phar.1839","volume":"36","author":"KS Hanna","year":"2016","unstructured":"Hanna KS (2016) A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy 36:e183\u2013e188. https:\/\/doi.org\/10.1002\/phar.1839","journal-title":"Pharmacotherapy"},{"key":"2635_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ajoc.2016.04.004","volume":"2","author":"SC Taylor","year":"2016","unstructured":"Taylor SC, Hrisomalos F, Linette GP, Rao PK (2016) A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy. Am J Ophthalmol Case Rep 2:23\u201325. https:\/\/doi.org\/10.1016\/j.ajoc.2016.04.004","journal-title":"Am J Ophthalmol Case Rep"},{"key":"2635_CR14","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","volume":"133","author":"D Mantopoulos","year":"2015","unstructured":"Mantopoulos D, Kendra KL, Letson AD, Cebulla CM (2015) Bilateral choroidopathy and serous retinal detachments during ipilimumab treatment for cutaneous melanoma. JAMA Ophthalmol 133:965\u2013967. https:\/\/doi.org\/10.1001\/jamaophthalmol.2015.1128","journal-title":"JAMA Ophthalmol"},{"key":"2635_CR15","doi-asserted-by":"publisher","first-page":"658","DOI":"10.3928\/23258160-20150610-10","volume":"46","author":"J Crews","year":"2015","unstructured":"Crews J, Agarwal A, Jack L, Xu D, Do DV, Nguyen QD (2015) Ipilimumab-associated retinopathy. Ophthalmic Surg Lasers Imaging Retina 46:658\u2013660. https:\/\/doi.org\/10.3928\/23258160-20150610-10","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"2635_CR16","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1001\/jamaophthalmol.2017.4872","volume":"135","author":"E Tsui","year":"2017","unstructured":"Tsui E, Madu A, Belinsky I, Yannuzzi LA, Freund KB, Modi YS (2017) Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment. JAMA Ophthalmol 135:1455\u20131457. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.4872","journal-title":"JAMA Ophthalmol"},{"key":"2635_CR17","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","volume":"6","author":"RK Wong","year":"2012","unstructured":"Wong RK, Lee JK, Huang JJ (2012) Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 6:423\u2013426. https:\/\/doi.org\/10.1097\/ICB.0b013e31824f7130","journal-title":"Retin Cases Brief Rep"},{"key":"2635_CR18","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/1346-8138.13612","volume":"44","author":"T Arai","year":"2017","unstructured":"Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R (2017) Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 44:975\u2013976. https:\/\/doi.org\/10.1111\/1346-8138.13612","journal-title":"J Dermatol"},{"key":"2635_CR19","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/ccr3.911","volume":"5","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Yamasaki O (2017) Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep 5:694\u2013700. https:\/\/doi.org\/10.1002\/ccr3.911","journal-title":"Clin Case Rep"},{"key":"2635_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09273948.2019.1583347","volume":"23","author":"CW Noble","year":"2019","unstructured":"Noble CW, Gangaputra SS, Thompson IA, Yuan A, Apolo AB, Lee JM, Papaliodis GN, Kodati S, Bishop R, Magone MT, Sobrin L, Sen HN (2019) Ocular adverse events following use of immune checkpoint inhibitors for metastatic malignancies. Ocul Immunol Inflamm 23:1\u20136. https:\/\/doi.org\/10.1080\/09273948.2019.1583347","journal-title":"Ocul Immunol Inflamm"},{"key":"2635_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamaophthalmol.2018.0920","volume":"136","author":"M Thomas","year":"2018","unstructured":"Thomas M, Armenti ST, Ayres MB, Demirci H (2018) Uveal effusion after immune checkpoint inhibitor therapy. JAMA Ophthalmol 136:553\u2013556. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.0920","journal-title":"JAMA Ophthalmol"},{"key":"2635_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09273948.2019.1577978","volume":"28","author":"MN Sun","year":"2020","unstructured":"Sun MN, Levinson RD, Filipowicz A, Anesi S, Kaplan HJ, Wang W, Goldstein DA, Gangaputra S, Swan RT, Sen HN, Gordon LK (2020) Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm 28:217\u2013227. https:\/\/doi.org\/10.1080\/09273948.2019.1577978","journal-title":"Ocul Immunol Inflamm"},{"key":"2635_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00262-018-2260-7","volume":"68","author":"W Wang","year":"2019","unstructured":"Wang W, Lam WC, Chen L (2019) Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. Cancer Immunol Immunother 68:85\u201395. https:\/\/doi.org\/10.1007\/s00262-018-2260-7","journal-title":"Cancer Immunol Immunother"},{"key":"2635_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000785","author":"BE O'Bryhim","year":"2018","unstructured":"O'Bryhim BE, Sychev Y, Rao PK (2018) Bilateral choroidal detachments secondary to ipilimumab and pembrolizumab use. Retin Cases Brief Rep. https:\/\/doi.org\/10.1097\/ICB.0000000000000785","journal-title":"Retin Cases Brief Rep"},{"key":"2635_CR25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.jtho.2018.04.026","volume":"13","author":"T Tamura","year":"2018","unstructured":"Tamura T, Akimoto E, Matsumoto C, Mori S, Nishi T, Kudo K, Kuyama S (2018) Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer. J Thorac Oncol 13:1606\u20131607. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.026","journal-title":"J Thorac Oncol"},{"key":"2635_CR26","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1080\/09273948.2018.1459733","volume":"27","author":"G Reid","year":"2019","unstructured":"Reid G, Lorigan P, Heimann H, Hovan M (2019) Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm 27:1012\u20131015. https:\/\/doi.org\/10.1080\/09273948.2018.1459733","journal-title":"Ocul Immunol Inflamm"},{"key":"2635_CR27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/ICB.0000000000000604","volume":"13","author":"HS Sandhu","year":"2019","unstructured":"Sandhu HS, Kolomeyer AM, Lau MK, Shields CL, Schuchter LM, Nichols CW, Aleman TS (2019) Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma. Retin Cases Brief Rep 13:103\u2013107. https:\/\/doi.org\/10.1097\/ICB.0000000000000604","journal-title":"Retin Cases Brief Rep"},{"key":"2635_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/CJI.0000000000000154","volume":"40","author":"M Bricout","year":"2017","unstructured":"Bricout M, Petre A, Amini-Adle M, Bezza W, Seve P, Kodjikian L, Dalle S, Thomas L (2017) Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother 40:77\u201382. https:\/\/doi.org\/10.1097\/CJI.0000000000000154","journal-title":"J Immunother"},{"key":"2635_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/ICB.0000000000000882","author":"KF Elwood","year":"2019","unstructured":"Elwood KF, Pulido JS, Ghafoori SD, Harper CA, Wong RW (2019) Choroidal neovascularization and chorioretinal atrophy in a patient with melanoma-associated retinopathy after ipilimumab\/nivolumab combination therapy. Retin Cases Brief Rep. https:\/\/doi.org\/10.1097\/ICB.0000000000000882","journal-title":"Retin Cases Brief Rep"},{"key":"2635_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1159\/000496682","volume":"10","author":"S Obata","year":"2019","unstructured":"Obata S, Saishin Y, Teramura K, Ohji M (2019) Vogt-Koyanagi-Harada disease-like uveitis during nivolumab (Anti-PD-1 antibody) treatment for metastatic cutaneous malignant melanoma. Case Rep Ophthalmol 10:67\u201374. https:\/\/doi.org\/10.1159\/000496682","journal-title":"Case Rep Ophthalmol"},{"key":"2635_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.2451","author":"C Rodriguez","year":"2019","unstructured":"Rodriguez C, Sieburth R, Newman S, Gaughan E, Shildkrot YE (2019) Bilateral mydriasis and serous retinal detachments associated with ipilimumab and 6-melanoma helper peptide vaccine for cutaneous melanoma. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2019.2451","journal-title":"JAMA Ophthalmol"},{"key":"2635_CR32","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","volume":"11","author":"MT Aaberg","year":"2017","unstructured":"Aaberg MT, Aaberg TM Jr (2017) Pembrolizumab administration associated with posterior uveitis. Retin Cases Brief Rep 11:348\u2013351. https:\/\/doi.org\/10.1097\/ICB.0000000000000368","journal-title":"Retin Cases Brief Rep"},{"key":"2635_CR33","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/CJI.0000000000000143","volume":"39","author":"S Diem","year":"2016","unstructured":"Diem S, Keller F, R\u00fcesch R, Maillard SA, Speiser DE, Dummer R, Siano M, Urner-Bloch U, Goldinger SM, Flatz L (2016) Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy? J Immunother 39:379\u2013382. https:\/\/doi.org\/10.1097\/CJI.0000000000000143","journal-title":"J Immunother"},{"key":"2635_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1001\/jamaophthalmol.2018.1851","volume":"136","author":"LA Acaba-Berrocal","year":"2018","unstructured":"Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, Ho AC, Dunn JP, Shields CL (2018) Birdshot-like chorioretinopathy associated with pembrolizumab treatment. JAMA Ophthalmol 136:1205\u20131207. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.1851","journal-title":"JAMA Ophthalmol"},{"key":"2635_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","volume":"256","author":"CD Conrady","year":"2018","unstructured":"Conrady CD, Larochelle M, Pecen P, Palestine A, Shakoor A, Singh A (2018) Checkpoint inhibitor-induced uveitis: a case series. Graefes Arch Clin Exp Ophthalmol 256:187\u2013191. https:\/\/doi.org\/10.1007\/s00417-017-3835-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2635_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaapos.2018.01.006","volume":"22","author":"ESY Park","year":"2018","unstructured":"Park ESY, Rabinowits G, Hamnvik OR, Dagi LR (2018) A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy. J AAPOS 22:310\u2013312. https:\/\/doi.org\/10.1016\/j.jaapos.2018.01.006","journal-title":"J AAPOS"},{"key":"2635_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ejca.2016.12.010","volume":"73","author":"T Amaral","year":"2017","unstructured":"Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, Garbe C (2017) The mitogen-activated protein kinase pathway in melanoma part I\u2014activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer 73:85\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.010","journal-title":"Eur J Cancer"},{"key":"2635_CR38","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S2213-2600(15)00026-0","volume":"3","author":"DF Heigener","year":"2015","unstructured":"Heigener DF, Gandara DR, Reck M (2015) Targeting of MEK in lung cancer therapeutics. Lancet Respir Med 3:319\u2013327. https:\/\/doi.org\/10.1016\/S2213-2600(15)00026-0","journal-title":"Lancet Respir Med"},{"key":"2635_CR39","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.ophtha.2017.05.038","volume":"124","author":"JH Francis","year":"2017","unstructured":"Francis JH, Habib LA, Abramson DH, Yannuzzi LA, Heinemann M, Gounder MM, Grisham RN, Postow MA, Shoushtari AN, Chi P, Segal NH, Yaeger R, Ho AL, Chapman PB, Catalanotti F (2017) Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy. Ophthalmology 124:1788\u20131798. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.038","journal-title":"Ophthalmology"},{"key":"2635_CR40","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1093\/annonc\/mdw100","volume":"27","author":"N Stjepanovic","year":"2016","unstructured":"Stjepanovic N, Velazquez-Martin JP, Bedard PL (2016) Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 27:998\u20131005. https:\/\/doi.org\/10.1093\/annonc\/mdw100","journal-title":"Ann Oncol"},{"key":"2635_CR41","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejca.2016.06.018","volume":"65","author":"U Urner-Bloch","year":"2016","unstructured":"Urner-Bloch U, Urner M, Jaberg-Bentele N, Frauchiger AL, Dummer R, Goldinger SM (2016) MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: long-term ophthalmic effects. Eur J Cancer 65:130\u2013138. https:\/\/doi.org\/10.1016\/j.ejca.2016.06.018","journal-title":"Eur J Cancer"},{"key":"2635_CR42","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","volume":"60","author":"L Zimmer","year":"2016","unstructured":"Zimmer L, Goldinger SM, Hofmann L et al (2016) Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60:210\u2013225. https:\/\/doi.org\/10.1016\/j.ejca.2016.02.024","journal-title":"Eur J Cancer"},{"key":"2635_CR43","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000439259","volume":"2","author":"MP Breazzano","year":"2015","unstructured":"Breazzano MP, Barker-Griffith AE (2015) Features of cutaneous malignant melanoma metastatic to the retina and vitreous. Ocul Oncol Pathol 2:80\u201385. https:\/\/doi.org\/10.1159\/000439259","journal-title":"Ocul Oncol Pathol"},{"key":"2635_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ophtha.2019.09.018","volume":"127","author":"JH Francis","year":"2020","unstructured":"Francis JH, Berry D, Abramson DH et al (2020) Intravitreous cutaneous metastatic melanoma in the era of checkpoint inhibition. Ophthalmology 127:240\u2013248. https:\/\/doi.org\/10.1016\/j.ophtha.2019.09.018","journal-title":"Ophthalmology"},{"key":"2635_CR45","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","volume":"28","author":"AM Menzies","year":"2017","unstructured":"Menzies AM, Johnson DB, Ramanujam S et al (2017) Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 28:368\u2013376. https:\/\/doi.org\/10.1093\/annonc\/mdw443","journal-title":"Ann Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02635-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02635-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T23:45:21Z","timestamp":1623887121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02635-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,17]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2635"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02635-3","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,17]]},"assertion":[{"value":"7 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was reviewed and approved by the Institutional Review Board of Severance Hospital, Seoul Korea (approval number: 4-2019-1100).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for informed consent for the retrospective study was waived by the Institutional Review Board.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}